CapsoVisionvsMerck & Company

CV and MRK stock compared: price, dividend, valuation and results, from SEC filings.

CV

CapsoVision, Inc.

$6.11

Value $328M

-3.17%
CV's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

CapsoVision (CV) has a market value of $328M and Merck & Company (MRK) $331B. Over the last year, with dividends, CV moved +14.6% and MRK +44.8%. Dividend yield: CV none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CV$328M

    MRK$331B

    MRK is 1,009 times CV

  • Revenue, 12 months

    CV$14M

    MRK$67.4B

    MRK is 4,840 times CV

  • Net income, 12 months

    CV-$29M

    MRK$2.5B

  • Operating margin

    CV-212.1%

    MRK–

  • ROIC

    CV-124.8%

    MRK3.9%

    128.7 points apart

  • P/E

    CV–

    MRK134.8

  • Dividend yield

    CV0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CV+14.6%

MRK+44.8%

100150200250DecFebAprJunAugOct
Returns by period
PeriodCVWith dividendsMRKWith dividends
1 year since November 19, 2025+14.6%Price +14.6%+44.8%Price +40.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CVCapsoVisionMRKMerck & Company

Valuation

CVMRK
Valuation
Price$6.11$133.72
Market value$328M$331B
Enterprise value (EV)$328M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B12.47.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

CVMRK
Results and growth
Revenue, 12 months$14M$67.4B
Net income, 12 months-$29M$2.5B
Free cash flow, 12 months-$29M$14.7B
Earnings per share, 12 months-$0.43$0.98
Revenue growth, year on year15.3%1.3%
Revenue growth a year, past+15.3%over 1 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CVMRK
Margins and returns on capital
Gross margin49.7%71.8%
Operating margin-212.1%–
Net margin-210.1%3.6%
ROIC-124.8%3.9%
ROE-156.5%5.2%

Balance sheet

CVMRK
Balance sheet
Cash–$9.7B
Total debt$780.0K$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

CVMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CV or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, CapsoVision or Merck & Company?

By market value, Merck & Company ($331B) is about 1,009.3 times CapsoVision ($328M), at today's prices.

How did CV and MRK stock do over the last 1 years?

Since November 19, 2025, CV's price moved +14.6% and MRK's +40.7%. With dividends: CV +14.6% (+14.6% a year), MRK +44.8% (+44.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, CV or MRK?

The dividend yield at today's price is none for CapsoVision and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, CapsoVision or Merck & Company?

Over the last twelve months, the net margin was -210.1% for CapsoVision and 3.6% for Merck & Company, and the operating margin -212.1% and –. Revenue was $14M and $67.4B.

Which is the better investment, CapsoVision or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.